Searchable abstracts of presentations at key conferences in endocrinology

ea0028p53 | Clinical practice/governance and case reports | SFEBES2012

Antiphospholipid syndrome and adrenal insufficiency: a case series

Whyte Martin , Grove Grace , McGowan Barbara , Carroll Paul , Powrie Jake

Introduction: Antiphospholipid syndrome (APS) is the association of anti-cardiolipin antibodies and venous & arterial thrombosis. APS accounts for <0.5% of cases of hypoadrenalism. We present a series of 5 such cases occurring at our institution plus a further patient identified with unilateral adrenal haemorrhage. Case 1 presented with nausea, vomiting and weight loss. Lupus anticoagulant positive. Commenced aspirin 300 mg. 6-weeks later represented with dehydration, ...

ea0028p159 | Nursing practise | SFEBES2012

Evaluation of a nurse-led telephone consultation service for adults with Hyperthyroidism due to Graves’ disease

Breen Louise , Powrie Jake , Kariyawasam Dulmini , Betal Dipannita , Carroll Paul

Hyperthyroidism due to Graves’ disease (GD) is traditionally managed in the secondary care ambulatory setting. Conventionally patients are required to attend for regular review at 4–12 weekly intervals, presenting practical difficulties for many adults. Nurse-led Telephone Consultations are gaining momentum in the care of long-term conditions. This Service Development Project (SDP) addressed whether or not a specialist nurse delivered telephone consultation could be ...

ea0025p37 | Clinical biochemistry | SFEBES2011

Polycythaemia in men treated with transdermal and intramuscular testosterone

Agustsson Tomas , McGowan Barbara , Powrie Jake , Thomas Stephen , Carroll Paul

Background: Testosterone replacement therapy has been shown to produce a wide range of benefits for men with hypogonadism with studies showing improvement in libido, bone density, muscle mass, body composition, mood, cognition, and erythopoiesis. The risks associated with testosterone replacement therapy are less well characterised and there is a lack of larger randomised trials. One recognised risk is polycythaemia. The aim of this study is to assess the frequency of polycyth...

ea0025p343 | Thyroid | SFEBES2011

Optimal use of thyroid antibody assays in the identification of auto-immune thyroid disease

Kariyawasam Dulmini , Chuah Lingling , Granville Swana , Karim Yousuf , Carroll Paul

Background: A variety of thyroid antibody assays are used in the diagnosis of auto-immune thyroid disease (AITD). Commonly both thyroid peroxidase (TPOab) and thyroglobulin antibodies (TGab) are measured but the added value of testing two markers has not been established.Method: We retrospectively collected clinical and laboratory data on 500 consecutive patients who had thyroid autoantibodies requested from a specialist endocrine department of a tertiar...

ea0021p265 | Pituitary | SFEBES2009

Gender differences in presentation and response to treatment for prolactin-secreting adenoma

Luck Sara , Carroll Paul , Powrie Jake , McGowan Barbara , Thomas Stephen

Context: Prolactinomas are the most common functioning pituitary adenomas & it is recognised that gender has an influence on presentation and management of this condition.Objective: To examine the effects of gender on presentation and response to treatment in a large cohort of adults with confirmed prolactinoma (MRI performed and macroprolactin excluded).Design & patients: This retrospective cohort study design used an elec...

ea0021p386 | Thyroid | SFEBES2009

Interpreting adrenal status in thyrotoxicosis

Breen Louise , McGowan Barbara , Carroll Paul , Thomas Stephen

A 19-year-old, female of West African descent presented with a 5 months history of thyrotoxicosis. The GP had commenced carbimazole. She had continuing clinical and biochemical thyrotoxicosis TSH <0.01 (0.3–5.5 mU/l), FT4 68.0 (9–20 pmol/l) and FT3 18.9 (3.4–5.6 pmol/l). Thyroid antibodies were present at elevated titre and technetium uptake scanning showed toxic diffuse hyperplasia with an uptake function of 37%, confirming Graves&#146...

ea0018p24 | (1) | MES2008

Surveillance of a slowly progressive non-benign adrenal incidentaloma

Charles Debbie-Ann , Liu Yuk-Fun , Jaques Audrey , Carroll Paul

Adrenal incidentalomas are tumours of the adrenal incidentally discovered during evaluation for non-adrenal disease. The National Institute of Health consensus definition usually excludes lesions found during evaluation for malignancy. We present a case of an initially non-secretory adrenal incidentaloma that progressively increased in size over 6 years and became hormonally active.A 78-year-old hypertensive male was found to have a right adrenal mass du...

ea0015p88 | Clinical practice/governance and case reports | SFEBES2008

Experience from the first two years of a dedicated clinic for adults with Turner syndrome

Doherty Emma , Powrie Jake , Thomas Stephen , Brackenridge Anna , Carroll Paul

Recently updated international guidelines recommend specialist surveillance of adults with Turner Syndrome (TS). In 2005, we established a dedicated TS clinic, attracting referrals from our general endocrine service and other specialities including primary care.Twenty-three patients currently attend of whom 9 were previously under endocrinology review. Karyotypes include 45XO (8/23), 45XO/46XrX (4/23), and 45XO/46XiXq (3/23). Mean (±S.D.</sma...

ea0056ep16 | Adrenal and Neuroendocrine Tumours | ECE2018

Patient experiences with continouous subcutaneous hydrocortisone infusion (CSHI)

Yeoh Phillip , Khoo Bernard , Carroll Paul , Aylwin Simon

We recently reported the impact of continous s.c. hydrocortisone infusion (CSHI) on weight, patient AddiQoL scores and healthcare cost savings on five patients. This poster is to follow up on all our patients experiences since started on the CSHI as well as qualitative feedback on the impact on their lives.This poster also gathered key points on how these patients managed their adrenal crisis....

ea0052p05 | (1) | UKINETS2017

Incidence of PCC/PGL in mutation positive family members at first contact

AhmedMohammed Isra , Velusamy Anand , McGowan Barbara , Izatt Louise , Powrie Jake , Obholzer Rupert , Carroll Paul

SDH mutations that contribute 15%–20% of PCC/PGL syndromes predispose to the development of tumours that originate from Adrenal, Parasympathetic and extra-adrenal sympathetic-associated chromaffin tissues. We conducted a retrospective analysis to identify the prevalence of PCC/PGL and elevated biomarkers during initial screening in patients newly identified as carrying a pathogenic SDH mutation.Method: Data collection from our random cohort of patie...